April 1, 2026: Patient Form Temporary Outage Notice – Patient forms will be unavailable tonight from 9:00 PM – 5:00 AM EST due to scheduled maintenance. Access will be restored on April 2, 2026, by 6:00 AM EST. Thank you for your patience.
An orally bioavailable, small molecule inhibitor of the N-terminal domain (NTD) of the androgen receptor (AR), with potential antineoplastic activity. Upon oral administration, AR inhibitor EPI-506 specifically binds to the NTD of AR, thereby inhibiting both AR activation and the AR-mediated signaling pathway. This inhibits cell growth in AR-overexpressing tumor cells. AR is overexpressed in prostate cancers and is involved in proliferation, survival and chemoresistance of tumor cells. Check for active clinical trials using this agent. (NCI Thesaurus)
Related Posts
Recent Posts
